Cost-effectiveness of the antithrombotic medications
| Drug | Mean (95% credible interval) | Cost-effectiveness† | ||||
|---|---|---|---|---|---|---|
| Cost, $* | Δ Cost | QALY | Δ QALY | ICER | ||
| Acetylsalicylic acid | 83 834 (83 427 to 84 241) | – | 4.89 (4.88 to 4.90) | – | – | – |
| Warfarin | 88 704 (88 268 to 89 140) | 4870 (4274 to 5466) | 5.11 (5.10 to 5.12) | 0.21 (0.21 to 0.23) | – | Dominated by extension |
| Apixaban, 5 mg | 92 056 (91 639 to 92 473) | 3352 (2749 to 3955) | 5.86 (5.85 to 5.86) | 0.74 (0.74 to 0.76) | 8517 (7915 to 9121) | Cost-effective |
| Edoxaban, 30 mg | 93 262 (92 849 to 93 675) | 1206 (620 to 1792) | 5.80 (5.79 to 5.81) | −0.06 (−0.07 to −0.05) | – | Absolutely dominated |
| Dabigatran, 110 mg | 94 670 (94 234 to 95 106) | 2614 (2011 to 3217) | 5.56 (5.56 to 5.57) | −0.29 (−0.30 to −0.28) | – | Absolutely dominated |
| Edoxaban, 60 mg | 97 929 (97 479 to 98 379) | 5872 (5260 to 6486) | 5.68 (5.68 to 5.69) | −0.17 (−0.18 to −0.16) | – | Absolutely dominated |
| Rivaroxaban, 20 mg | 107 425 (106 892 to 107 958) | 15 369 (14 692 to 16 046) | 5.57 (5.56 to 5.57) | −0.29 (−0.30 to −0.28) | – | Absolutely dominated |
| Dabigatran, 150 mg | 114 818 (114 159 to 115 477) | 22 761 (21 982 to 23 542) | 5.05 (5.04 to 5.06) | −0.80 (−0.82 to −0.79) | – | Absolutely dominated |